Obesity Drugs in the Payer Market: What to Expect
Payers won’t let these products break the bank.
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk
Conditions require a disciplined approach to drug pricing.
The Payer Value Deficit in Orphan Drugs
Shift focus in orphan and ultra-orphan messaging to clinical benefit.
Payer Key Business Factors for Orphan Product Launches
Supporting health plan clinical preparation and financial modeling.
485 Route 1 South,Building F, Suite 210Iselin, NJ 08830